

# Metallothionein involvement in mitochondrial function and disease: a metabolomics investigation

J. Zander Lindeque, M.Sc.

12662275

Thesis submitted for the degree *Philosophiae Doctor* in Biochemistry at the Potchefstroom  
Campus of the North-West University

**Promotor:** Prof. F.H. van der Westhuizen

Centre for Human Metabonomics, North-West University (Potchefstroom Campus), South  
Africa.

**Co-promotor:** Dr. R. Louw

Centre for Human Metabonomics, North-West University (Potchefstroom Campus), South  
Africa.

September 2011



## ABSTRACT

One of the many recorded adaptive responses in respiratory chain complex I deficient cells is the over-expression of the small metal binding proteins, metallothioneins (MTs). The antioxidant properties of MTs putatively protect the deficient cells against oxidative damage, thus limiting further damage and impairment of enzymes involved in energy production. Moreover, the role of metallothioneins in supplying metal cofactors to enzymes and transcription factors in order to promote energy metabolism was previously proposed, which could accompany their role as antioxidants. This view is supported by the observations that MT knockout mice tend to become moderately obese, implying a lower energy metabolic rate. Hence, the involvement of metallothioneins in mitochondrial function and disease cannot be ignored. However, this association is still very vague due to the diversity of their functions and the complexity of the mitochondrion. The use of systems biology technology and more specifically metabolomics technology was thus employed to clarify this association by investigating the metabolic differences between wild type and MT knockout mice in unchallenged conditions as well as when mitochondrial function (energy metabolism) was challenged with exercise and/or a high-fat diet. The metabolic differences between these mice were also studied when complex I of the respiratory chain was inhibited with rotenone. The metabolome content of different tissues and bio-fluids were examined in an untargeted fashion using three standardized analytical platforms and the data mined using modern metabolomics and related statistical methods. Clear metabolic differences were found between the wild type and MT knockout mice during unchallenged conditions. These metabolic differences were persisted and were often amplified when mitochondrial metabolism was specifically challenged through exercise, high-fat intake or complex I inhibition. The data pointed to an overall reduced metabolic rate in the MT knockout mice and possible insulin resistance after the interventions which imply (and confirm) the involvement of MTs in promoting energy metabolism in the wild type mice.

Keywords: Metallothioneins, mitochondria, metabolomics, metallothionein-knockout, chemometrics



“When a thing was new, people said ‘*it is not true*’. Later when the truth became obvious, people said ‘*it is not important*’. And when its importance could not be denied, people said ‘*anyway, it is not new*’.” – William James (1842 – 1920)

“Whether we model the reality or only a shadow of it, we form a better understanding of the intricate biochemical processes and their scattering in living systems.” (Weckwerth, 2003)



# ACKNOWLEDGEMENTS

I would like to express my sincere gratitude to the following people and institutions for their contribution to this study:

My promoter, **Prof. Francois van der Westhuizen**, and co-promoter, **Dr. Roan Louw**, for their guidance, support and overall input in this study. They are extraordinary supervisors, scientists, teachers and people.

**Prof. Juan Hidalgo** at the Autonomous University of Barcelona for providing the metallothionein knockout mice, experimental samples and for his input in this study.

**Mr. Peet Jansen van Rensberg**, for teaching and assisting me with the analytical instruments and for his input and advice.

**Dr. Gerhard Koekemoer** (at the Statistical Consultation Services, NWU) for his expert advice and assistance with the statistics.

**Mr. Cor Bester**, **Mrs. Antoinette Fick** and **Mr. Petri Bronkhorst** at the NWU Animal Research Centre for their expert assistance with the mice.

Co-students in the Mito-Lab, **Marianne, Ané, Karien** and **Walter**, for the part they played in the rotenone study.

**BioPAD**, **National Research Foundation (NRF)** and **NWU-Centre for Human Metabonomics** for financial support.

**Mr. Lesley Wyldbore** for language and grammar editing.

**My family and wife (Jo-anne)** for their unconditional support, love and encouragement and also for my wife's assistance with the processing of my metabolic data.

And finally, I am deeply grateful for the talents and opportunity **the Lord** gave me through the grace of our **Lord Jesus Christ**. All honors go to the Lord.

# TABLE OF CONTENTS

LIST OF ABBREVIATIONS AND SYMBOLS .....	I
LIST OF FIGURES .....	V
LIST OF EQUATIONS .....	XI
LIST OF TABLES .....	XII
CHAPTER ONE: INTRODUCTION .....	1
CHAPTER TWO: REVIEW: THE INVOLVEMENT OF METALLOTHIONEINS IN MITOCHONDRIAL FUNCTION AND DISEASE .....	4
2.1. Introduction .....	4
2.2. Mitochondrial function and disease .....	5
2.2.1. Biological importance and function .....	5
2.2.2. Mitochondrial disorders and oxidative stress .....	6
2.3. Metallothioneins .....	8
2.3.1. General properties of metallothioneins .....	8
2.3.2. Biological importance and function of metallothioneins .....	9
2.3.2.1. Metal homeostasis .....	10
2.3.2.2. Heavy metal detoxification .....	11
2.3.2.3. Free radical scavenging .....	12
2.3.2.4. Free radical scavenging mechanisms .....	12
2.3.2.5. MT research models and current trends .....	13
2.3.3. Metallothionein localization .....	14
2.4. Functional associations between metallothioneins and the mitochondrion .....	16
2.4.1. Metallothioneins, ROS and oxidative stress .....	18
2.4.2. Apoptosis .....	20
2.4.3. The metallothionein-glutathione cycle .....	22
2.4.4. Energy metabolism .....	24
2.4.4.1. Metal homeostasis and enzyme activity .....	25
2.4.4.2. Enzyme inhibition and re-activation .....	27
2.4.4.3. Mitochondrial permeability transition pore .....	28
2.4.4.4. Nucleotide complex formation .....	29
2.4.4.5. Cytochrome c and Coenzyme Q .....	30
2.4.5. Nuclear- and mitochondrial DNA transcription regulation .....	31
2.5. Conclusions and future prospects .....	33



CHAPTER THREE: STUDY DESIGN.....	34
3.1. Problem statement.....	34
3.2. Study aim.....	36
3.3. Experimental approaches and design.....	37
3.3.1. Part1: Establishing metabolomics analyses, data processing and statistical methods for high-throughput and precision work.....	37
3.3.1.1. Experimental samples.....	37
3.3.1.2. Selected metabolomics approach.....	38
3.3.1.3. Analytical platforms of choice.....	39
3.3.2. Part 2: A metabolomics investigation on the involvement of MTs in mitochondrial function: Metabolic differences in WT, MT1+2KO and MT3KO mice when challenged with exercise and high fat intake (Chapter 4).....	40
3.3.3. Part 3: A metabolomics investigation on the involvement of MTs in mitochondrial function and disease: Metabolic differences in WT and MT1+2KO mice during complex I dysfunction (Chapter 5).....	42
 CHAPTER FOUR: A METABOLOMICS INVESTIGATION ON THE INVOLVEMENT OF MTs IN MITOCHONDRIAL FUNCTION: METABOLIC DIFFERNCES IN WT, MT1+2KO AND MT3KO MICE WHEN CHALLENGED WITH EXERCISE AND HIGH FAT INTAKE.....	44
4.1. Introduction.....	44
4.2. Materials and methodology.....	45
4.2.1. Materials.....	45
4.2.2. Experimental groups and samples.....	46
4.2.3. Sample preparation.....	47
4.2.3.1. Deproteinization of plasma samples for metabolic footprinting.....	47
4.2.3.2. Metabolome extraction from tissue samples for metabolic fingerprinting.....	48
4.2.3.3. Oximation and silylation.....	49
4.2.3.4. Methylation.....	49
4.2.3.5. Sample blocking.....	50
4.2.4. Instrumentation and analysis.....	50
4.2.4.1. Positive scan LC-MS.....	50
4.2.4.2. GC-MS analysis of trimethylsilyl esters.....	51
4.2.4.3. GC-MS analysis of FAMES.....	51
4.2.5. Data extraction.....	51
4.2.5.1. LC-MS data.....	51
4.2.5.2. GC-MS data.....	52
4.2.6. Data pre-processing and normalization.....	53
4.2.6.1. LC-MS data.....	53

4.2.6.2.	GC-MS data.....	53
4.2.6.3.	Batch correction of plasma and gastrocnemius data.....	54
4.2.7.	Data pre-treatment, statistical analysis and bio-informatics.....	54
4.2.7.1.	Univariate analysis.....	54
4.2.7.2.	Multivariate analysis.....	55
4.3.	Results and Discussion.....	57
4.3.1.	Evaluating the effect of exercise on the metabolome and exometabolome.....	57
4.3.1.1.	Plasma exometabolome.....	57
4.3.1.2.	Gastrocnemius metabolome.....	62
4.3.1.3.	Liver metabolome.....	67
4.3.1.4.	Brain metabolome.....	78
4.3.1.5.	Biological interpretation of the effect of exercise on the metabolism.....	85
4.3.2.	Evaluating the effect of high fat intake on the metabolome and exometabolome.....	87
4.3.2.1.	Plasma exometabolome.....	87
4.3.2.2.	Gastrocnemius metabolome.....	90
4.3.2.3.	Liver metabolome.....	93
4.3.2.4.	Brain metabolome.....	98
4.3.2.5.	Biological interpretation of the effect of the HFD on the metabolism.....	101
4.3.3.	Evaluating the combined effect of exercise and high fat intake on the metabolome and exometabolome.....	105
4.3.3.1.	Plasma exometabolome.....	105
4.3.3.2.	Gastrocnemius metabolome.....	108
4.3.3.3.	Liver metabolome.....	112
4.3.3.4.	Brain metabolome.....	117
4.3.3.5.	Biological interpretation of the effect of high-fat diet and exercise on the metabolism.....	120
4.3.4.	Metabolic differences between WT, MT1+2KO and MT3KO mice during unchallenged conditions.....	121
4.3.4.1.	Plasma exometabolome.....	121
4.3.4.2.	Gastrocnemius metabolome.....	123
4.3.4.3.	Liver metabolome.....	126
4.3.4.4.	Brain metabolome.....	133
4.3.4.5.	Biological interpretation of the metabolic differences between the WT, MT1+2KO and MT3KO mice.....	137
4.3.5.	Metabolic differences between WT, MT1+2KO and MT3KO mice after challenged with exercise.....	142
4.3.5.1.	Plasma exometabolome.....	142
4.3.5.2.	Gastrocnemius metabolome.....	144
4.3.5.3.	Liver metabolome.....	148

4.3.5.4.	Brain metabolome.....	156
4.3.5.5.	Biological interpretation of the metabolic differences between the WT, MT1+2KO and MT3KO mice when challenged with exercise.....	161
4.3.6.	Metabolic differences between WT, MT1+2KO and MT3KO mice after challenged with a high fat intake.....	163
4.3.6.1.	Plasma exometabolome.....	163
4.3.6.2.	Gastrocnemius metabolome.....	167
4.3.6.3.	Liver metabolome.....	169
4.3.6.4.	Brain metabolome.....	177
4.3.6.5.	Biological interpretation of the metabolic differences between the WT, MT1+2KO and MT3KO mice when challenged with a high fat intake.....	182
4.3.7.	Metabolic difference between WT, MT1+2KO and MT3KO mice after challenged with a high fat intake and exercise.....	186
4.3.7.1.	Plasma exometabolome.....	186
4.3.7.2.	Gastrocnemius metabolome.....	188
4.3.7.3.	Liver metabolome.....	192
4.3.7.4.	Brain metabolome.....	198
4.3.7.5.	Biological interpretation of the metabolic differences between the WT, MT1+2KO and MT3KO mice when challenged with a high fat intake and exercise.....	202
4.4.	Chapter summary.....	205

CHAPTER FIVE:	THE INVOLVEMENT OF MTs IN MITOCHONDRIAL FUNCTION AND DISEASE: METABOLIC DIFFERENCES IN WT AND MT1+2KO MICE DURING COMPLEX I DYSFUNCTION.....	207
5.1.	Introduction.....	207
5.2.	Materials and Methodology.....	208
5.2.1.	Materials.....	208
5.2.2.	Test animals.....	208
5.2.3.	Genotyping.....	209
5.2.4.	Experimental procedures.....	209
5.2.5.	Sample collection.....	210
5.2.6.	Sample preparation.....	211
5.2.6.1.	Deproteinization of serum samples for metabolic footprinting.....	211
5.2.6.2.	Preparation of urine samples for metabolic footprinting.....	212
5.2.6.3.	Oximation and silylation.....	212
5.2.6.4.	Methylation.....	212
5.2.6.5.	Sample blocking.....	213
5.2.7.	Instrumentation and analysis.....	213

5.2.7.1.	Positive scan LC-MS.....	213
5.2.7.2.	GC-MS of trimethylsilyl esters.....	213
5.2.7.3.	GC-MS of FAMES.....	213
5.2.8.	Data extraction.....	213
5.2.8.1.	LC-MS data.....	213
5.2.8.2.	GC-MS data.....	213
5.2.9.	Data pre-processing and normalisation.....	214
5.2.9.1.	LC-MS data.....	214
5.2.9.2.	GC-MS data.....	214
5.2.10.	Data pretreatment, statistical analysis and bio-informatics.....	214
5.2.10.1.	Univariate analysis.....	214
5.2.10.2.	Multivariate analysis.....	214
5.3.	Results and discussion.....	215
5.3.1.	Genotyping.....	215
5.3.2.	Evaluating the effect of rotenone treatment in the exometabolome.....	216
5.3.2.1.	Snapshot of serum exometabolome.....	217
5.3.2.2.	Urine exometabolome: 14 hour overview of metabolic state.....	221
5.3.2.3.	Biological interpretation of the effect of the rotenone treatment and complex I inhibition on the metabolism.....	226
5.3.3.	Metabolic differences between WT and MT1+2KO mice during unchallenged conditions.....	227
5.3.3.1.	Snapshot of serum exometabolome.....	227
5.3.3.2.	Urine exometabolome: 14 hour overview of metabolic state.....	230
5.3.3.3.	Biological interpretation of metabolic differences between the WT and MT1+2KO mice during unchallenged conditions.....	233
5.3.4.	Metabolic differences between WT and MT1+2KO mice during complex I dysfunction.....	235
5.3.4.1.	Snapshot of serum exometabolome.....	235
5.3.4.2.	Urine exometabolome: 14 hour overview of metabolic state.....	239
5.3.4.3.	Biological interpretation of metabolic differences between the WT and MT1+2KO mice during complex I dysfunction.....	242
5.4.	Chapter summary.....	246
CHAPTER SIX:	CONCLUSIONS AND FUTURE PROSPECTS.....	248
6.1.	Study aims and objectives: motivation and accomplishments.....	248
6.1.1.	The establishment and standardisation of a high-throughput and precise metabolomics data generation, data processing and statistics workflow.....	250
6.1.2.	Metabolic differences between WT, MT1+2KO and MT3KO mice during unchallenged conditions and when mitochondrial metabolism was	

specifically challenged with exercise and/or high-fat intake .....	251
6.1.3. Metabolic differences between WT and MT1+2KO mice during unchallenged conditions and when complex I is dysfunctional.....	253
6.2. New concepts and Hypotheses .....	254
6.2.1. Hypothetical roles of MTs in mitochondria function and disease.....	255
6.3. Critical assessment of this study.....	259
6.4. Final conclusion and future prospects.....	261

REFERENCES.....	263
-----------------	-----

ANNEXURE A: METABOLOMICS: TECHNOLOGY, APPROACHES AND  
DATA MINING.....

A.1.1.1. Terminology.....	294
A.1.3.1. GC-MS: overview, advantages and limitations.....	300
A.1.3.2. LC-MS: overview, advantages and limitations.....	302
A.1.4.2.1. Metabolite extraction from tissue samples and cells.....	305
A.1.4.2.2. Deproteinization of blood plasma and serum.....	307
A.1.4.2.3. Preparation of urine.....	308
A.1.4.4.1. Oximation and silylation.....	312
A.1.4.4.2. Methylation.....	315
A.2.2.2.1. LC-MS data extraction.....	320
A.2.2.2.2. GC-MS data extraction.....	323

A.2.3. Data pre-processing.....	324
A.2.4. Data normalisation and pre-treatment.....	327

A.2.4.1.	Data normalisation.....	327
A.2.4.1.1.	Normalisation to sample weight .....	327
A.2.4.1.2.	Normalisation to internal standard(s).....	328
A.2.4.1.3.	Normalisation to total signal.....	328
A.2.4.2.	Data pre-treatment.....	329
A.2.4.2.1.	Centering.....	330
A.2.4.2.2.	Auto-scaling.....	330
A.2.4.2.3.	Pareto scaling.....	330
A.2.4.2.4.	VAST scaling.....	331
A.2.4.2.5.	Log transformation.....	331
A.2.4.2.6.	Power and fourth root transformation.....	332
A.2.4.2.7.	Data pre-treatment combinations in the literature .....	332
A.2.5.	Statistical analysis of the data using chemometrics and univariate methods.....	333
A.2.5.1.	Univariate statistics.....	334
A.2.5.2.	Chemometrics techniques.....	334
A.2.5.2.1.	Principal component analysis (PCA).....	335
A.2.5.2.2.	Independent component analysis (ICA).....	336
A.2.5.2.3.	Partial least squares (projection to latent structures) – discriminant analysis (PLS-DA).....	337
A.3.	Annexure summary.....	337

ANNEXURE B:	METABOLOMICS: METHODOLOGY CONSIDERATIONS, DEVELOPMENT AND STANDARDISATION.....	338
B.1.	Introduction.....	338
B.2.	Standardising the extraction and LC-MS analysis of polar metabolite.....	338
B.2.1.	LC-MS analysis of polar metabolites.....	338
B.2.2.	Selection of internal and external standards.....	339
B.2.2.1.	Materials and method.....	339
B.2.2.2.	Results and discussion.....	340
B.2.3.	Metabolite extraction from tissue sample for metabolic fingerprinting.....	343
B.2.3.1.	Materials and methods .....	344
B.2.3.2.	Results and discussion.....	345
B.2.4.	Deproteinization of plasma/serum samples for metabolic footprinting.....	348
B.2.4.1.	Materials and method.....	349
B.2.4.2.	Results and discussion .....	349
B.2.5.	Preparation of urine samples for metabolic footprinting.....	351
B.2.5.1.	Materials and method.....	351
B.2.5.2.	Results and discussion.....	351
B.3.	Standardising the extraction, trimethylsilylation and GC-MS analysis of primary	

metabolites.....	352
B.3.1. GC-MS analysis of trimethylsilyl esters.....	352
B.3.2. Selection of internal and external standards.....	352
B.3.2.1. Materials and methods.....	353
B.3.2.2. Results and discussions.....	354
B.3.3. Metabolite extraction from tissue samples for metabolic fingerprinting.....	355
B.3.3.1. Materials and methods.....	355
B.3.3.2. Results and discussion.....	356
B.3.4. Deproteinization of plasma/serum samples for metabolic footprinting.....	357
B.3.5. Preparation of urine samples for metabolic footprinting.....	357
B.3.5.1. Materials and method.....	358
B.3.5.2. Results and discussion.....	359
B.3.6. Silylation and oximation of metabolites to give trimethylsilyl esters.....	360
B.3.6.1. Materials and methods.....	361
B.3.6.2. Results and discussions.....	363
B.4. Standardising the extraction, methylation and GC-MS analysis of lipids and fatty acids.....	365
B.4.1. GC-MS analysis of FAMES.....	365
B.4.2. Selection of internal and external standards.....	365
B.4.2.1. Materials and methods.....	366
B.4.2.2. Results and discussions.....	366
B.4.3. Metabolite extraction from tissue samples for metabolic fingerprinting.....	367
B.4.3.1. Materials and methods.....	367
B.4.3.2. Results and discussion.....	368
B.4.4. Deproteinization of plasma/serum samples for metabolic footprinting.....	368
B.4.5. Preparation of urine samples for metabolic footprinting.....	368
B.4.6. Methylation of lipids to give fatty acid methyl esters.....	369
B.4.6.1. Materials and methods.....	369
B.4.6.2. Results and discussions.....	370
B.5. Annexure summary.....	372

ANNEXURE C: METABOLOMICS DATA PROCESSING AND STATISTICAL ANALYSIS: APPROACH AND METHOD SELECTION FOR A HIGH-THROUGHPUT WORKFLOW.....	373
C.1. Introduction.....	373
C.2. Raw data cleanup and extraction.....	373
C.2.1. First order data cleaning.....	373
C.2.2. Data extraction.....	374
C.2.2.1. LC-MS data extraction.....	374

C.2.2.1.1.	MassHunter-MPP untargeted data extraction procedure .....	375
C.2.2.1.2.	MassHunter-MPP targeted data extraction procedure.....	376
C.2.2.2.	GC-MS data extraction.....	376
C.2.2.2.1.	Materials and methods.....	377
C.2.2.2.2.	Results and discussion .....	378
C.2.2.2.3.	AMDIS - MET-IDEA data extraction procedure.....	382
C.3.	Data pre-processing.....	383
C.3.1.	LC-MS data pre-processing.....	383
C.3.1.1.	Materials and methods.....	385
C.3.1.2.	Results and discussion.....	385
C.3.2.	GC-MS data pre-processing.....	386
C.3.2.1.	Materials and methods.....	387
C.3.2.2.	Results and discussion.....	388
C.4.	Data normalisation and pre-treatment.....	389
C.4.1.	Data normalisation.....	389
C.4.1.1.	Normalisation to sample weight.....	389
C.4.1.2.	Normalisation to internal standard(s).....	390
C.4.1.3.	Normalisation to total signal.....	390
C.4.1.4.	Batch normalisation and signal correction.....	391
C.4.1.5.	Data pre-treatment.....	392
C.5.	Statistical analysis.....	393
C.5.1.	Univariate statistics.....	393
C.5.2.	Multivariate statistics.....	394
C.5.2.1.	Principal component analysis (PCA).....	394
C.5.2.2.	Partial least square discriminant analysis.....	395
C.6.	Annexure summary.....	395
ANNEXURE D:	RE-EVALUATING THE INFLUENCE OF MOISTURE IN DERIVATIZATION: DOES RESIDUAL WATER IN DRIED URINE AND TISSUE SAMPLES MATTER?.....	396
D.1.	Introduction.....	396
D.2.	Materials and methods .....	396
D.3.	Results and discussion .....	397
ANNEXURE E:	BODY WEIGHT GAIN OF WT, MT1+2KO AND MT3KO MICE ON NORMAL AND HIG-FAT DIET.....	400
ANNEXURE F:	THE COLLABORATIVE INVESTIGATION OF THE ROLE OF MTs IN MITOCHONDRIAL FUNCTION AND DISEASE: THE	



	ROTENONE STUDY.....	403
F.1.	Description of the collaborative study.....	403
F.2.	Supplementary data showing complex I inhibition.....	403
ANNEXURE G:	SUPPLEMENTARY MATERIAL: CD.....	407
ANNEXURE H:	PUBLICATIONS AND CONFERENCE PROCEEDINGS.....	408
ANNEXURE I:	CO-AUTHOR CONSENT.....	409

## LIST OF ABBREVIATIONS AND SYMBOLS

### SYMBOLS

$\alpha$	alpha
$\beta$	beta
m	milli ( $10^{-3}$ )
$\mu$	micro ( $10^{-6}$ )
n	nano ( $10^{-9}$ )
$^{\circ}\text{C}$	degrees Celsius
%	percentage
>	greater than
<	less than
< v.c	below visual cut-off
~	approximately
#	number
x g	g-force ( $9.80665 \text{ m/s}^2$ )

### ABBREVIATIONS

ACN	acetonitrile
ADP	adenosine diphosphate
Ag	silver
ATP	adenosine triphosphate
bp	base pairs
BSA	bovine serum albumin
BSTFA	O-bis(trimethylsilyl)trifluoroacetamide
CCMN	Cross-Contribution robust Multiple internal standard Normalization
Cd	cadmium
CI	complex I (NADH:ubiquinone oxidoreductase)
CII	complex II (succinate:ubiquinone oxidoreductase)
CIII	complex III (coenzyme Q - cytochrome c reductase)

CIV	complex IV (cytochrome c oxidase)
CoQ	coenzyme Q (ubiquinone)
Cu	copper
CV	coefficient of variance
cyt c	cytochrome c
Da	Dalton
DMPA	N,N-dimethyl-L-phenylalanine
DNA	deoxyribonucleic acid
EC	environmental control
EDTA	ethylene diamine tetra-acetate
ESI	electrospray ionisation
ETC	electron transport chain
EtOH	ethanol
FAD	flavin adenine dinucleotide
FbF	find by formula
FbI	find by ion
g	gram
GC	gas chromatography
GPx	glutathione peroxidase
GSH	reduced glutathione
GSSG	oxidized glutathione (dimer)
h	hour
HCl	hydrochloric acid
HFD	high-fat diet
HFD-E	high-fat diet & exercise
Hz	Hertz
IMs	important metabolites

kDa	kilo Dalton
KOH	potassium hydroxide
I	liter
LC	liquid chromatography
M	molar
MeOH	methanol
MFE	molecular feature extraction
min	minutes
ml	milliliter
mM	milli-molar
MPP	Mass Profiler Professional
MS	mass spectrometry
MSTFA	N-Methyl-N-trifluoroacetamide
MSTUS	mass spectrometry total useful signal
MT	metallothionein
MT-1	metallothionein isoform 1
MT-2	metallothionein isoform 2
MT-3	metallothionein isoform 3
MT-4	metallothionein isoform 4
MTKO	metallothionein knockout (unspecified, referring to both MT1+2KO and MT3KO)
MT1+2KO	metallothioneins isoforms 1 and 2 knockout
MT3KO	metallothioneins isoform 3 knockout
mtDNA	mitochondrial DNA
MTs	metallothioneins
m/z	mass to charge
NAD(H)	nicotinamide adenine dinucleotide (reduced)
nM	nano-molar
nm	nanometer
OH <sup>·</sup>	hydroxyl radical
OXPPOS	oxidative phosphorylation

PBS	phosphate buffered saline
PC	principal component
PCA	principal component analysis
PCR	polymerase chain reaction
PLS	Partial least squares (projection to latent structures)
PLS-DA	partial least squares discriminant analysis
PLSR	partial least squares regression
ppm	parts per million
QC	quality control
Q-TOF	quadrupole time of flight
RNS	reactive nitrogen species
ROS	reactive oxygen species
RP	reverse phase
RT	retention time; rotenone treatment
SD	standard deviation
SOD	superoxide dismutase
TIC	total ion chromatogram
TOF	time of flight
VAST	variable stability
VC	vehicle control
WT	wild type
Zn	zinc

## LIST OF FIGURES

<b>Figure #</b>	<b>Title</b>	<b>Page #</b>
2.1	Cellular localization of EGFP-MT-1B fusion protein in HeLa cells visualised by confocal microscopy	16
2.2	Summarized schematic presentation of the putative interactions of MTs with the mitochondrion	17
2.3	The metallothioneins-glutathione redox and metal exchange cycle	23
3.1	Illustration of the common workflow of a metabolomics experiment	38
3.2	Schematic presentation of the experimental and metabolomics strategy designed to investigate the involvement of MTs in normal mitochondrial function and metabolism	41
3.3	Schematic presentation of the experimental and metabolomics strategy to comprehensively investigate the role of MTs in mitochondrial disease (complex I deficiency)	42
4.1	Experimental procedures for investigating the role of MTs in challenged mitochondrial function	46
4.2	Sample preparation and analytical procedures for liver (A), plasma (B), brain (C) and gastrocnemius (D) samples	48
4.3	The two-dimensional comparison of experimental groups	56
4.4	The effect of the exercise, high-fat diet and high-fat diet with exercise on the plasma exometabolome as detected with untargeted LC-MS analyses	58
4.5	The effect of exercise, high-fat diet and high-fat diet with exercise on the gastrocnemius metabolome as detected with LC-MS analyses	63
4.6	The effect of exercise, high-fat diet and high-fat diet with exercise on the gastrocnemius metabolome as detected with silylation-GC-MS analyses	64
4.7	Preliminary PCA results of the liver samples showing clear differences between male and female mice	67
4.8	The effect of exercise, high-fat diet and high-fat diet with exercise on the liver metabolome of female mice as detected with LC-MS analyses	68
4.9	The effect of exercise, high-fat diet and high-fat diet with exercise on the liver metabolome of male mice as detected with LC-MS analyses	69
4.10	The effect of exercise, high-fat diet and high-fat diet with exercise on the liver metabolome of female mice as detected with silylation-GC-MS analyses	70
4.11	The effect of exercise, high-fat diet and high-fat diet with exercise on the liver	71

	metabolome of male mice as detected with silylation-GC-MS analyses	
4.12	The effect of exercise, high-fat diet and high-fat diet with exercise on the liver metabolome of female mice as detected with methylation-GC-MS analyses	72
4.13	The effect of exercise, high-fat diet and high-fat diet with exercise on the liver metabolome of male mice as detected with methylation-GC-MS analyses	73
4.14	The effect of exercise, high-fat diet and high-fat diet with exercise on the brain metabolome as detected with LC-MS analyses	79
4.15	The effect of exercise, high-fat diet and high-fat diet with exercise on the brain metabolome as detected with silylation-GC-MS analyses	80
4.16	The mitochondrion - the hub of metabolism and energy production	86
4.17	Proposed metabolic implications of a long term high-fat diet	103
4.18	Glutathione is synthesized and catabolised in the $\gamma$ -glutamyl cycle	104
4.19	Differences in the plasma exometabolome composition of WT, MT1+2KO and MT3KO mice as detected with untargeted LC-MS analyses	122
4.20	Differences in the gastrocnemius metabolome composition of WT, MT1+2KO and MT3KO mice as detected with untargeted LC-MS analyses	124
4.21	Differences in the gastrocnemius metabolome composition of WT, MT1+2KO and MT3KO mice as detected with silylation GC-MS analyses	124
4.22	Differences in the liver metabolome composition of WT, MT1+2KO and MT3KO male mice as detected with untargeted LC-MS analyses	128
4.23	Differences in the liver metabolome composition of WT, MT1+KO and MT3KO female mice as detected with untargeted LC-MS analyses	128
4.24	Differences in the liver metabolome composition of WT, MT1+2KO and MT3KO male mice as detected with silylation-GC-MS analyses	129
4.25	Differences in the liver metabolome composition of WT, MT1+2KO and MT3KO female mice as detected with silylation-GC-MS analyses	129
4.26	Differences in the liver lipidome composition of WT, MT1+2KO and MT3KO male mice as detected with methylation-GC-MS	130
4.27	Differences in the liver lipidome composition of WT, MT1+2KO and MT3KO female mice as detected with methylation-GC-MS	130
4.28	Differences in the brain metabolome composition of WT, MT1+2KO and MT3KO mice as detected with untargeted LC-MS analyses	135
4.29	Differences in the brain metabolome composition of WT, MT1+2KO and MT3KO mice as detected with silylation-GC-MS analyses	135
4.30	Cyclic-AMP stimulates glycogenolysis and lipolysis	138
4.31	Biosynthesis of different lipid species from phosphatidate (1-acyl-sn-glycerol-3-	140

	phosphate)	
4.32	An overview of biosynthesis linked to the central metabolism	141
4.33	Differences in the plasma exometabolome composition of WT, MT1+2KO and MT3KO mice after exercise as detected with untargeted LC-MS analyses	143
4.34	Differences in the gastrocnemius metabolome composition of the WT, MT1+2KO and MT3KO mice after exercise as detected with untargeted LC-MS analyses	146
4.35	Differences in the gastrocnemius metabolome composition of the WT, MT1+2KO and MT3KO mice after exercise as detected with silylation-GC-MS analyses	146
4.36	Differences in the liver metabolome composition of WT, MT1+2KO and MT3KO male mice after exercise as detected with untargeted LC-MS analyses	150
4.37	Differences in the liver metabolome composition of WT, MT1+2KO and MT3KO female mice after exercise as detected with untargeted LC-MS analyses	150
4.38	Differences in the liver metabolome composition of WT, MT1+2KO and MT3KO male mice after exercise as detected with silylation-GC-MS analyses	151
4.39	Differences in the liver metabolome composition of WT, MT1+2KO and MT3KO female mice after exercise as detected with silylation-GC-MS analyses	151
4.40	Differences in the liver lipidome composition of WT, MT1+2KO and MT3KO male mice after exercise as detected with methylation-GC-MS analyses	152
4.41	Differences in the liver lipidome composition of WT, MT1+2KO and MT3KO female mice after exercise as detected with methylation-GC-MS analyses	152
4.42	Differences in the brain metabolome composition after exercise as detected with untargeted LC-MS analyses	157
4.43	Differences in the brain metabolome composition after exercise as detected with silylation-GC-MS analyses	157
4.44	Differences in the plasma exometabolome composition of WT, MT1+2KO and MT3KO mice as detected with untargeted LC-MS analyses	163
4.45	Differences in the gastrocnemius metabolome composition of WT, MT1+2KO and MT3KO mice as detected with untargeted LC-MS analyses	168
4.46	Differences in the gastrocnemius metabolome composition of WT, MT1+2KO and MT3KO mice as detected with silylation GC-MS analyses	168
4.47	Differences in the liver metabolome composition of WT, MT1+2KO and MT3KO male mice as detected with untargeted LC-MS analyses	171
4.48	Differences in the liver metabolome composition of WT, MT1+2KO and MT3KO female mice as detected with untargeted LC-MS analyses	171
4.49	Differences in the liver metabolome composition of WT, MT1+2KO and MT3KO male mice as detected with silylation GC-MS analyses	172
4.50	Differences in the liver metabolome composition of WT, MT1+2KO and MT3KO	172



	female mice as detected with silylation GC-MS analyses	
4.51	Differences in the liver lipidome composition of WT, MT1+2KO and MT3KO male mice as detected with methylation GC-MS analyses	173
4.52	Differences in the liver lipidome composition of WT, MT1+2KO and MT3KO female mice as detected with methylation GC-MS analyses	173
4.53	Differences in the brain metabolome composition of WT, MT1+2KO and MT3KO mice as detected with untargeted LC-MS analyses	178
4.54	Differences in the brain metabolome composition of WT, MT1+2KO and MT3KO mice as detected with silylation GC-MS analyses	178
4.55	Interplay of organs and metabolic pathways	184
4.56	Differences in the plasma exometabolome composition of WT, MT1+2KO and MT3KO mice as detected with untargeted LC-MS analyses	186
4.57	Differences in the gastrocnemius metabolome composition of WT, MT1+2KO and MT3KO mice as detected with untargeted LC-MS analyses	190
4.58	Differences in the gastrocnemius metabolome composition of WT, MT1+2KO and MT3KO mice as detected with silylation GC-MS analyses	190
4.59	Differences in the liver metabolome composition of WT, MT1+2KO and MT3KO male mice as detected with untargeted LC-MS analyses	193
4.60	Differences in the liver metabolome composition of WT, MT1+2KO and MT3KO female mice as detected with untargeted LC-MS analyses	193
4.61	Differences in the liver metabolome composition of WT, MT1+2KO and MT3KO male mice as detected with silylation GC-MS analyses	194
4.62	Differences in the liver metabolome composition of WT, MT1+2KO and MT3KO female mice as detected with silylation GC-MS analyses	194
4.63	Differences in the liver lipidome composition of WT, MT1+2KO and MT3KO male mice as detected with methylation GC-MS analyses	195
4.64	Differences in the liver lipidome composition of WT, MT1+2KO and MT3KO female mice as detected with methylation GC-MS analyses	195
4.65	Differences in the brain metabolome composition of WT, MT1+2KO and MT3KO mice as detected with untargeted LC-MS analyses	199
4.66	Differences in the brain metabolome composition of WT, MT1+2KO and MT3KO mice as detected with silylation GC-MS analyses	199
5.1	Experimental procedures for investigating the role of MTs in mitochondrial function during complex I inhibition	210
5.2	Sample preparation and analytical procedures	211
5.3	The two-dimensional comparison of experimental groups	215

5.4	Example of PCR and gel electrophoresis genotyping	216
5.5	The effect of rotenone treatment on the serum exometabolome as detected with LC-MS and silylation-GC-MS	219
5.6	The effect of rotenone treatment on the urinary exometabolome as detected with LC-MS and silylation-GC-MS	223
5.7	Differences in the serum exometabolome composition of WT and MT1+2KO mice as detected with untargeted LC-MS analyses	228
5.8	Differences in the serum exometabolome composition of WT and MT1+2KO mice as detected with silylation GC-MS analyses	228
5.9	Differences in the urine exometabolome composition of WT and MT1+2KO mice as detected with untargeted LC-MS analyses	231
5.10	Differences in the urine exometabolome composition of WT and MT1+2KO mice as detected with silylation GC-MS analyses	231
5.11	Differences in the serum exometabolome composition of WT and MT1+2KO mice as detected with untargeted LC-MS analyses	236
5.12	Differences in the serum exometabolome composition of WT and MT1+2KO mice as detected with silylation GC-MS analyses	236
5.13	Differences in the urinary exometabolome composition of WT and MT1+2KO mice as detected with untargeted LC-MS analyses	240
5.14	Differences in the urinary exometabolome composition of WT and MT1+2KO mice as detected with silylation GC-MS analyses	240
5.15	Metabolic pathways involved in perturbation and the involvement of insulin	243
5.16	Proposed events leading to moderate insulin resistance and counteractions of MTs	245
6.1	Schematic presentation illustrating the hypothetical roles of MTs in mitochondrial and insulin function	257
A.1	The 'omics' cascade	294
A.2	Approaches to study metabolic responses in biological systems	297
A.3	The oximation and silylation reaction	313
A.4	The base-catalyzed methylation reaction	316
A.5	The process of data mining to acquire relevant biological information from complex metabolomics data	317
A.6	The three main steps involved in data extraction	319
A.7	Multivariate vs. univariate statistics in grouping and validation	333
A.8	PCA scores plot (A) and loadings plot (B).	336

B.1	Overlaid LC-MS chromatograms of all the tested standards (A) and representative mice samples (B).	341
B.2	Data and score plots indicating the repeatable metabolite extraction of liver (soft) and muscle (hard) tissue samples	345
B.3	Data and score plots indicating the metabolite extraction at different temperatures and different organic solvents.	347
B.4	Data and score plots of plasma samples deproteinized with acetonitrile and ultrafiltration.	350
B.5	Comparative (mirror) data plot of acetonitrile treated and untreated urine samples.	352
B.6	Chromatograms of all the tested standards and mice tissue/bio-fluid samples.	354
B.7	Experimental strategy to study the difference in monophasic and biphasic metabolite extraction for silylation and GC-MS analyses.	356
B.8	Experimental strategy to investigate different urine preparation methods for silylation - GC-MS.	358
B.9	Representative chromatograms of mice urine prepared with acetonitrile (A) and organic acid extraction (B).	359
B.10	Experimental procedure to validate selected oximation and silylation conditions.	362
B.11	Validation results of the selected oximation and silylation conditions.	364
B.12	Overlaid GC-MS chromatograms of all the tested standards (A) and representative mice samples (B).	367
B.13	Overlaid chromatogram of the FAME (A) and PUFA (B) mix alone and after silylation with BSTFA.	371
C.1	Comparison of the variability of the extracted data of five replicate samples with numerous software options.	379
C.2	Data and score plots of LC-MS data before and after pre-processing.	386
C.3	Data and score plots of GC-MS data before and after pre-processing.	388
C.4	An S-type bar plot of the average Euclidean distances determined from the loadings matrix.	394
D.1	Experimental strategy to study the influence of moisture on silylation.	397
D.2	Chromatograms showing the influence of moisture on silylation.	398
E.1	Body weight gain of the WT, MT1+2KO and MT3KO mice that was fed a high-fat diet or a control (chow) diet	400
E.2	Absolute weights of liver, gonadal and inguinal fat deposit from the WT, MT1+2KO and MT3KO mice	401

F.1	Schematic presentation of the strategy designed to comprehensively investigate the role of MTs in mitochondrial disease (complex I deficiency)	404
F.2	Box and whiskers plots showing the different OXPHOS enzyme activities in the heart	405
F.3	Box and whiskers plots showing the different OXPHOS enzyme activities in the skeletal muscle	406
F.4	Bar plot presentation of the enzyme quantities as determined using BN-PAGE and western blot analyses of heart mitochondrial fractions	406

## LIST OF EQUATIONS

Equation #	Title	Page #
C.1	Equation for determining effect size between two groups	394

## LIST OF TABLES

<b>Table #</b>	<b>Title</b>	<b>Page #</b>
4.1	Important plasma metabolites that differed markedly between the exercise and control group of each strain	59
4.2	Pathway analysis results from the plasma LC-MS IMs obtained when the exercise group of each mouse strain was compared to their respective control group	60
4.3	Important metabolites that differed markedly between the control and exercise group in the gastrocnemius	65
4.4	Pathway analysis results from the gastrocnemius IMs obtained after the exercise group was compared to the control	65
4.5	Important metabolites that differed markedly between the control and exercise group in the liver	74
4.6	Pathway analysis results from the liver IMs obtained after the exercise group was compared to the control	76
4.7	Important metabolites that differed markedly between the control and exercise group in the brain	81
4.8	Pathway analysis results from the brain IMs obtained after the exercise group was compared to the control	83
4.9	Important plasma metabolites that differed markedly between the control- and HFD group for each genotype, respectively	88
4.10	Pathway analysis results from the plasma LC-MS IMs obtained after the HFD group was compared to the control	89
4.11	Important metabolites that differed markedly between the control and HFD group in the gastrocnemius	91
4.12	Pathway analysis results from the plasma LC-MS IMs obtained after the HFD group was compared to the control	92
4.13	Important metabolites that differed markedly between the control and HFD group in the liver	94
4.14	Pathway analysis results from the liver IMs obtained after the HFD group was compared to the control	96
4.15	Important metabolites that differed markedly between the control and HFD group in the brain	98
4.16	Pathway analysis results from the brain IMs obtained after the HFD group was compared to the control	100

4.17	Important plasma metabolites that differed markedly between the control and HFD-E group	106
4.18	Pathway analysis results from the plasma IMs obtained after the HFD-E group was compared to the control	107
4.19	Important metabolites in the gastrocnemius that differed markedly between the control and HFD-E group	108
4.20	Pathway analysis results from the gastrocnemius IMs obtained after the HFD-E group was compared to the control	110
4.21	Important hepatic metabolites that differed markedly between the control and HFD-E group	113
4.22	Pathway analysis results from the liver IMs obtained after the HFD-E group was compared to the control	116
4.23	Important metabolites from the brain that differed markedly between the control and HFD-E group	118
4.24	Pathway analysis results from the brain IMs obtained after the HFD-E group was compared to the control	120
4.25	Important plasma metabolites that differed markedly between the strains	123
4.26	Important gastrocnemius metabolites that differed markedly between the strains	125
4.27	Pathway analysis results from the gastrocnemius IMs obtained after the MT knockouts were compared to the WT	125
4.28	Important hepatic metabolites that differed markedly between the strains	131
4.29	Pathway analysis results of the IMs obtained after the males and females MT knockout mice were compared to the WT mice	133
4.30	Important brain metabolites that differed markedly between the strains	136
4.31	Pathway analysis results from the IMs obtained after the MT knockout mice were compared to the WT	136
4.32	Important plasma metabolites that differed markedly between the strains after exercise	144
4.33	Pathway analysis results from the plasma IMs obtained after the MT knockouts were compared to the WT	144
4.34	The important gastrocnemius metabolites that differed markedly between the strains after exercise	147
4.35	Pathway analysis results of the IMs obtained after the MT knockout mice was compared to the WT.	147
4.36	Important liver metabolites that differed markedly between the strains after exercise	153
4.37	Pathway analysis results of the IMs obtained after the male and female MT knockout mice was compared to the WT	155

4.38	The important brain metabolites that differed markedly between the strains after exercise.	158
4.39	Pathway analysis results of the IMs obtained after the MT knockout mice were compared to the WT mice	160
4.40	Important plasma metabolites that differed markedly between the strains after a long term HFD	164
4.41	Pathway analysis results from the plasma IMs obtained after the MT knockouts were compared to the WT	165
4.42	Important metabolites in the gastrocnemius that differed markedly between the strains after a long term HFD	169
4.43	Pathway analysis results from the gastrocnemius IMs obtained after the MT knockouts were compared to the WT	169
4.44	Important hepatic metabolites that differed markedly between the strains after a long term HFD	174
4.45	Pathway analysis results from the hepatic IMs obtained after the MT knockouts were compared to the WT	176
4.46	Important brain metabolites that differed markedly between the strains after a long term HFD	179
4.47	Pathway analysis results from the brain IMs obtained after the MT knockouts were compared to the WT	181
4.48	Important plasma metabolites that differed markedly between the strains after a long term HFD and one hour swim	187
4.49	Pathway analysis results from the plasma IMs obtained after the MT knockouts were compared to the WT	187
4.50	Important gastrocnemius metabolites that differed markedly between the strains after a long term HFD and one hour swim	191
4.51	Pathway analysis results from the gastrocnemius IMs obtained after the MT knockouts were compared to the WT	191
4.52	Important hepatic metabolites that differed markedly between the strains after a long term HFD and one hour swim	196
4.53	Pathway analysis results from the liver IMs obtained after the MT knockouts were compared to the WT	197
4.54	Important brain metabolites that differed markedly between the strains after a long term HFD and one hour swim	200
4.55	Pathway analysis results from the brain IMs obtained after the MT knockouts were compared to the WT	201

5.1	Important serum metabolites that differed markedly between the VC and RT groups	220
5.2	Pathway analysis results from the serum IMs obtained after the RT group was compared to the VC	221
5.3	Important urinary metabolites that differed markedly between the VC and RT groups	224
5.4	Pathway analysis results from the urine IMs obtained after the RT group was compared to the VC	225
5.5	Important serum metabolites that differed markedly between the strains during unchallenged conditions	229
5.6	Pathway analysis results from the serum IMs obtained after the strains were compared	230
5.7	Important urinary metabolites that differed markedly between the VC and RT groups during unchallenged conditions	232
5.8	Pathway analysis results from the urine IMs obtained after the strains were compared	232
5.9	Important serum metabolites that differed markedly between the VC and RT groups after complex I was inhibited	237
5.10	Pathway analysis results from the serum IMs obtained after the strains were compared	237
5.11	Important urinary metabolites that differed markedly between the VC and RT groups after complex I was inhibited	241
5.12	Pathway analysis results from the urine IMs obtained after the strains were compared	241
A.1	Summarised advantages and disadvantages of GC-MS vs. LC-MS	301
B.1	List of compounds tested for the selection of standards.	340
B.2	Mass similarities of standards and naturally abundant metabolites.	342
B.3	List of compounds tested for the selection of standards.	353
B.4	Metabolome coverage of the tested monophasic and biphasic metabolite extraction procedures.	357
B.5	List of compounds tested for the selection of standards.	366
B.6	Lipidome coverage of the monophasic and biphasic metabolite extraction methods in terms of detected FAMES after methylation	368
C.1	List of GC-MS data extraction software packages investigated	377
C.2	The amount of missing values (zeros) incorporated in the extracted data matrices from several tested software	381